Fiche publication
Date publication
avril 2026
Journal
Cells
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BRAVETTI Pierre
,
Pr GHIRINGHELLI François
Tous les auteurs :
Richert I, Chalus L, Pinteur B, Bravetti P, Tortorelli C, Alzeeb G, Ghiringhelli F
Lien Pubmed
Résumé
Hapten-based immunotherapies represent a promising strategy to enhance the immunogenicity of tumor antigens and promote antitumor immune responses. Chemical conjugation of small haptens to antigens generates novel antigenic determinants that increase immune recognition. Mechanistic studies indicate that haptenation enhances antigen uptake, dendritic cell maturation, and the activation of both cellular and humoral immunity. In preclinical models, hapten-modified antigens induce robust immune activation, tumor regression, and durable immune memory. Clinically, dinitrophenyl-modified autologous tumor cell vaccines elicit delayed-type hypersensitivity responses and clonal T-cell expansion, with evidence of clinical activity and a favorable safety profile. However, their clinical benefit remains to be confirmed in larger, randomized studies. Emerging strategies include in situ haptenation and bihaptenized or stressed hapten-modified allogeneic platforms, which aim to expand epitope diversity and enhance immune priming. Hapten-based immunotherapies offer a clinically feasible approach to converting poorly immunogenic tumors into effective immune targets.
Mots clés
delayed-type hypersensitivity, dendritic cells, haptenation, immunotherapies, tumor-associated antigens
Référence
Cells. 2026 04 22;15(9):
